Sangui Bio has a strong and broad patent portfolio, that is managed by the legal and patent firm – Spruson and Ferguson. The portfolio comprises three patent applications currently undergoing national phase examination based on recent discoveries in red blood cell biology and one provisional application. The first PCT application published in April 2017 and has been granted in four jurisdictions.